Gankyrin-mediated interaction between cancer cells and tumor-associated macrophages facilitates prostate cancer progression and androgen deprivation therapy resistance

References

• Huggins C, Hodges CV. Studies on Prostatic Cancer. I. The Effect of Castration, of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate. J Urol. 1972;167(2):948–15. doi:10.1016/S0022-5347(02)80307-X.
   Google Scholar
• Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. NEJM. 2019;381(2):121–131. doi:10.1056/NEJMoa1903835.
   PubMed Web of Science ®Google Scholar
• Chi KN, Agarwal N, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez Soto Á, Merseburger AS, Özgüroğlu M, Uemura H, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. NEJM. 2019;381(1):13–24. doi:10.1056/NEJMoa1903307.
   PubMed Web of Science ®Google Scholar
• Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES. Update on Systemic Prostate Cancer Therapies: management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. Eur Urol. 2019;75(1):88–99. doi:10.1016/j.eururo.2018.03.028.
   PubMed Web of Science ®Google Scholar
• Arora Vivek K, Schenkein E, Murali R, Subudhi Sumit K, Wongvipat J, Balbas Minna D, Shah N, Cai L, Efstathiou E, Logothetis C, et al. Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade. Cell. 2013;155(6):1309–1322. doi:10.1016/j.cell.2013.11.012.
   PubMed Web of Science ®Google Scholar
• Paschalis A, Sharp A, Welti JC, Neeb A, Raj GV, Luo J, Plymate SR, de Bono JS. Alternative splicing in prostate cancer. Nat Rev Clin Oncol. 2018;15(11):663–675. doi:10.1038/s41571-018-0085-0.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, et al. AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. NEJM. 2014;371(11):1028–1038. doi:10.1056/NEJMoa1315815.
   PubMed Web of Science ®Google Scholar
• Huang H, Wang C, Liu F, Li HZ, Peng G, Gao X, Dong KQ, Wang HR, Kong DP, Qu M, et al. Reciprocal Network between Cancer Stem-Like Cells and Macrophages Facilitates the Progression and Androgen Deprivation Therapy Resistance of Prostate Cancer. Clin Cancer Res. 2018;24(18):4612–4626. doi:10.1158/1078-0432.CCR-18-0461.
   PubMed Web of Science ®Google Scholar
• Wang C, Peng G, Huang H, Liu F, Kong DP, Dong KQ, Dai LH, Zhou Z, Wang KJ, Yang J, et al. Blocking the Feedback Loop between Neuroendocrine Differentiation and Macrophages Improves the Therapeutic Effects of Enzalutamide (MDV3100) on Prostate Cancer. Clin Cancer Res. 2018;24(3):708–723. doi:10.1158/1078-0432.CCR-17-2446.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zheng D, Zhou T, Song H, Hulsurkar M, Su N, Liu Y, Wang Z, Shao L, Ittmann M, et al. Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers. Nat Commun. 2018;9(1):5.
   PubMedGoogle Scholar
• Kato M, Placencio-Hickok VR, Madhav A, Haldar S, Tripathi M, Billet S, Mishra R, Smith B, Rohena-Rivera K, Agarwal P, et al. Heterogeneous cancer-associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner. Oncogene. 2019;38(5):716–730. doi:10.1038/s41388-018-0461-3.
   PubMed Web of Science ®Google Scholar
• Sun Y. Tumor microenvironment and cancer therapy resistance. Cancer Lett. 2016;380(1):205–215. doi:10.1016/j.canlet.2015.07.044.
   PubMed Web of Science ®Google Scholar
• Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49–61. doi:10.1016/j.immuni.2014.06.010.
   PubMed Web of Science ®Google Scholar
• Ginhoux F, Schultze JL, Murray PJ, Ochando J, Biswas SK. New insights into the multidimensional concept of macrophage ontogeny, activation and function. Nat Immunol. 2016;17(1):34–40. doi:10.1038/ni.3324.
   PubMed Web of Science ®Google Scholar
• Escamilla J, Schokrpur S, Liu C, Priceman SJ, Moughon D, Jiang Z, Pouliot F, Magyar C, Sung JL, Xu J, et al. CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy. Cancer Res. 2015;75(6):950–962. doi:10.1158/0008-5472.CAN-14-0992.
   PubMed Web of Science ®Google Scholar
• Camacho-Moll ME, Macdonald J, Looijenga LHJ, Rimmer MP, Donat R, Marwick JA, Shukla CJ, Carragher N, Jørgensen A, Mitchell RT. The oncogene Gankyrin is expressed in testicular cancer and contributes to cisplatin sensitivity in embryonal carcinoma cells. BMC Cancer. 2019;19(1). doi:10.1186/s12885-019-6340-7.
   PubMed Web of Science ®Google Scholar
• Chen J, Bai M, Ning C, Xie B, Zhang J, Liao H, Xiong J, Tao X, Yan D, Xi X, et al. Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway. Oncogene. 2015;35(19):2506–2517. doi:10.1038/onc.2015.316.
   PubMed Web of Science ®Google Scholar
• Zhen C, Chen L, Zhao Q, Liang B, Gu YX, Bai Z, Wang K, Xu X, Han Q, Fang D, et al. Gankyrin promotes breast cancer cell metastasis by regulating Rac1 activity. Oncogene. 2012;32(29):3452–3460. doi:10.1038/onc.2012.356.
   PubMed Web of Science ®Google Scholar
• Luo T, Fu J, Xu A, Su B, Ren Y, Li N, Zhu J, Zhao X, Dai R, Cao J, et al. PSMD10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression. Autophagy. 2016;12(8):1355–1371. doi:10.1080/15548627.2015.1034405.
   PubMed Web of Science ®Google Scholar
• Wang C, Li Y, C-m C, X-m Z, Ma J, Huang H, Y-n W, T-y H, Zhang J, X-w P, et al. Gankyrin is a novel biomarker for disease progression and prognosis of patients with renal cell carcinoma. EBioMedicine. 2019;39:255–264. doi:10.1016/j.ebiom.2018.12.011.
   PubMed Web of Science ®Google Scholar
• Wang C, Wang Y, Hong T, Cheng B, Gan S, Chen L, Zhang J, Zuo L, Li J, Cui X. Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma. Cell Death Dis. 2020;11(2):117. doi:10.1038/s41419-020-2306-6.
   PubMed Web of Science ®Google Scholar
• Sakurai T, Yada N, Hagiwara S, Arizumi T, Minaga K, Kamata K, Takenaka M, Minami Y, Watanabe T, Nishida N, et al. Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma. Cancer Sci. 2017;108(10):1996–2003. doi:10.1111/cas.13341.
   PubMed Web of Science ®Google Scholar
• Riahi MM, Sistani NS, Zamani P, Abnous K, Jamialahmadi K. Correlation of Gankyrin oncoprotein overexpression with histopathological grade in prostate cancer. Neoplasma. 2017;64(5):732–737. doi:10.4149/neo_2017_511.
   PubMed Web of Science ®Google Scholar
• Kim TD, Oh S, Lightfoot SA, Shin S, Wren JD, Janknecht R. Upregulation of PSMD10 caused by the JMJD2A histone demethylase. Int J Clin Exp Med. 2016;9:10123–10134.
   PubMed Web of Science ®Google Scholar
• Vanaja DK, Cheville JC, Iturria SJ, Young CYF. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 2003;63:3877–3882.
   PubMed Web of Science ®Google Scholar
• Takayama KI, Suzuki T, Fujimura T, Yamada Y, Takahashi S, Homma Y, Suzuki Y, Inoue S. Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF. Proc Natl Acad Sci U S A. 2017;114(39):10461–10466. doi:10.1073/pnas.1706076114.
   PubMed Web of Science ®Google Scholar
• Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, et al. ROR-gamma drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med. 2016;22(5):488–496. doi:10.1038/nm.4070.
   PubMed Web of Science ®Google Scholar
• Bieniasz-Krzywiec P, Martin-Perez R, Ehling M, Garcia-Caballero M, Pinioti S, Pretto S, Kroes R, Aldeni C, Di Matteo M, Prenen H, et al. Podoplanin-Expressing Macrophages Promote Lymphangio-genesis and Lymphoinvasion in Breast Cancer. Cell Metab. 2019;30(5):917–936 e910. doi:10.1016/j.cmet.2019.07.015.
   PubMed Web of Science ®Google Scholar
• Sahraei M, Chaube B, Liu Y, Sun J, Kaplan A, Price NL, Ding W, Oyaghire S, Garcia-Milian R, Mehta S, et al. Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response. J Clin Invest. 2019;129(12):5518–5536. doi:10.1172/JCI127125.
   PubMed Web of Science ®Google Scholar
• Chen K, Cao Q, Song Z, Ruan H, Wang C, Yang X, Bao L, Wang K, Cheng G, Xu T, et al.: Targeting the KIF4A/AR axis to reverse endocrine therapy resistance in castration-resistant prostate cancer. Clin Cancer Res 2019.
   Google Scholar
• Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, Manyam GC, Korentzelos D, Park S, Tang Z, et al. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019;25(22):6839–6851. doi:10.1158/1078-0432.CCR-19-0317.
   PubMed Web of Science ®Google Scholar
• Higashitsuji H, Higashitsuji H, Itoh K, Sakurai T, Nagao T, Sumitomo Y, Masuda T, Dawson S, Shimada Y, Mayer RJ, et al. The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53. Cancer Cell. 2005;8(1):75–87.
   PubMed Web of Science ®Google Scholar
• Erb HHH, Oster MA, Gelbrich N, Cammann C, Thomas C, Mustea A, Stope MB. Enzalutamide-induced Proteolytic Degradation of the Androgen Receptor in Prostate Cancer Cells Is Mediated Only to a Limited Extent by the Proteasome System. Anticancer Res. 2021;41(7):3271–3279. doi:10.21873/anticanres.15113.
   PubMed Web of Science ®Google Scholar
• Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921–R925. doi:10.1016/j.cub.2020.06.081.
   PubMed Web of Science ®Google Scholar
• Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson AM, Saad F. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods. 2009;348(1–2):9–17. doi:10.1016/j.jim.2009.06.004.
   PubMed Web of Science ®Google Scholar
• Wang C, Chen J, Zhang Q, Li W, Zhang S, Xu Y, Wang F, Zhang B, Zhang Y, Gao WQ. Elimination of CD4(low)HLA-G(+) T cells overcomes castration-resistance in prostate cancer therapy. Cell Res. 2018;28(11):1103–1117. doi:10.1038/s41422-018-0089-4.
   PubMedGoogle Scholar
• Cortesi F, Delfanti G, Grilli A, Calcinotto A, Gorini F, Pucci F, Luciano R, Grioni M, Recchia A, Benigni F, et al. Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression. Cell Rep. 2018;22(11):3006–3020. doi:10.1016/j.celrep.2018.02.058.
   PubMed Web of Science ®Google Scholar
• Chen PC, Cheng HC, Wang J, Wang SW, Tai HC, Lin CW, Tang CH. Prostate cancer-derived CCN3 induces M2 macrophage infiltration and contributes to angiogenesis in prostate cancer microenvironment. Oncotarget. 2014;5(6):1595–1608. doi:10.18632/oncotarget.1570.
   PubMedGoogle Scholar
• Li C, Zhang Y, Yan S, Zhang G, Wei W, Qi Z, Li B. Alternol triggers immunogenic cell death via reactive oxygen species generation. Oncoimmunology. 2021;10(1):1952539. doi:10.1080/2162402X.2021.1952539.
   PubMed Web of Science ®Google Scholar